According to a recent clinical publication and study in The Journal of The National Cancer Institute, researchers have stated that in patients with extensive actinic keratosis, Celecoxib might be useful in the prevention of nonmelanoma skin cancers.
In the U.S., more and more young adults are falling victims to this malignant nonmelanoma skin cancers, which is the most common form of cancers. Exposure to UV rays is considered to be the primary cause behind this form of cancer and since years researchers have been studying methods to counteract skin cancers, including the use of sunscreens, which only had a relatively modest effect in preventing cancers.
The researchers, headed by Craig A. Elmets, M.D. at the University of Alabama, Birmingham, conducted a ‘double-blind and placebo-controlled’ experiment with 240 random people with actinic keratoses. The results showed that the number of nonmelanoma skin cancers in the persons taking Celecoxib is significantly lower than those in the placebo group.
According to the researchers, ‘ The findings of this study, which showed that the celecoxib –treated individuals developed fewer non melanoma skin cancers than placebo-treated individuals, suggest that cyclooxygenase inhibitors may provide an additional benefit to sunscreens in the prevention of nonmelanoma skin cancers’.
Moreover, further research and trials of celecoxib on colorectal odoma only proved its efficiency on later stages of tumor developments.
Further studies are being going on to determine its effects on the number of precancerous lesions.